NCT05965687CompletedPhase 3
Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to determine the efficacy and safety of Normobaric Hyperoxia combined with intravenous thrombolysis for acute ischemic stroke.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 1230 (actual)
- First submitted
- 7 Jun 2023
- Start date
- 17 Aug 2023
- Primary completion date
- 16 Feb 2026
- Lead sponsor
- Ji Xunming,MD,PhD
- Diseases
- Stroke
- NCT number
- NCT05965687
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 1230
- From 17 Aug 2023 to the primary completion date, 16 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- two weeks of major surgery;
- Heparin treatment was received within 24 h;
- Thrombin inhibitors or factor Xa inhibitors were used within 48 h;
- Participation in other clinical trials within 3 months prior to screening;
Other illness
- Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);
- Past history of intracranial hemorrhage;
- A history of severe head trauma or stroke within 3 months;
- A history of intracranial or spinal surgery within 3 months;
- A history of gastrointestinal or urinary bleeding within 3 weeks;
- Active visceral bleeding;
- Severe, sustained hypertension (Systolic Blood Pressure \>185 mmHg or Diastolic Blood Pressure \>110 mmHg);
- Hereditary or acquired bleeding constitution;
- Onset with seizures;
- Active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;
- Patients with upper gastrointestinal bleeding or nausea or vomiting so that they cannot cooperate with the mask to inhale oxygen;
Lab values
- Baseline blood glucose of \<50mg/dL (2.78 mmol) or \>400mg/dL (22.20 mmol);
- Oral warfarin anticoagulant with international normalized ratio(INR)\>1.7 or prothrombin time(PT)\>15 s;
- Propensity for acute bleeding, including platelet counts of less than 100×109/ L or otherwise;
Other
- Rapid neurological function improvement, NIHSS score less than 5 points;
- Presence of proximal arterial occlusion on computed tomographic angiography(CTA)/magnetic resonance angiography(MRA) (e.g., intracranial internal carotid artery(ICA), middle cerebral artery(MCA)-M1, and vertebrobasilar arteries);
- Massive anterior cerebral infarction identified by CT or MRI (ASPECT \< 6 or lesions larger than one third of the territory of the middle cerebral artery);
- Intended to proceed endovascular treatment;
- Pregnant women, or planning to become pregnant during the trial;
- Arterial puncture was performed at the hemostasis site that was not easily compressed within 1 week;
- Intracranial tumors, large intracranial aneurysms;
- Aortic arch dissection was found;
- Severe liver and kidney dysfunction;
- Patients with anemia or polycythemia vera or other situations that require urgent oxygen inhalation;
- Life expectancy \< 1 year;
- Patients who could not complete the 90-day follow-up;
- Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.
Who the study is looking for
- Age≥18 years;
- The time from onset to randomization is within 4.5 hours of onset;
- The clinical diagnosis is acute ischemic stroke (the criteria followed the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018);
- Baseline NIHSS (at the time of randomization) should be ≥5 and ≤25 points;
- Pre-stroke mRS score≤1 points;
- Informed consent from the patient or surrogate.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuan Wu Hospital, Capital Medical University Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.